Pharmaceutical Continuous Manufacturing Market Scope And Analysis

  • Report Code : TIPRE00008245
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Pharmaceutical Continuous Manufacturing Market Scope and Key Players Analysis by 2031

Buy Now


Pharmaceutical Continuous Manufacturing Market Report Scope

Report Attribute Details
Market size in 2023 US$ 2.08 Billion
Market Size by 2031 US$ 4.67 Billion
Global CAGR (2023 - 2031) 10.6%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product
  • Integrated Systems
  • Semi-Continuous Systems
  • Controls
By Application
  • End Product Manufacturing
  • API Manufacturing
By End User
  • Full-Scale Manufacturing Companies
  • R&D Departments
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • GEA Group
  • Coperion GmbH
  • Gericke AG
  • Glatt GmbH
  • Hosokawa Micron Group
  • Munson Machinery Co Inc
  • Powrex Corp
  • Thermo Fisher Scientific Inc
  • Freund vector Corporation
  • Fette Compacting
  • Pharmaceutical Continuous Manufacturing Market News and Recent Developments

    The Pharmaceutical Continuous Manufacturing market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Pharmaceutical Continuous Manufacturing market are listed below:

    • South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience has broken ground on an approximately 4,200 m2 expansion of its L House vaccine manufacturing facility in Andong, Gyeongsangbuk-do, South Korea, which will serve as the production base for pneumococcal conjugate vaccine candidate GBP410, jointly developed by SK Bioscience and Sanofi, who are co-investing in the expansion. (SK Bioscience, Press Release, March 2024)
    • Phlow Corp., a US-based essential medicines public benefit company, announced strategic alliances with both Virginia Commonwealth University’s (VCU) Medicines for All Institute and AMPAC Fine Chemicals to provide contract continuous manufacturing research and development (R&D) services for small molecule pharmaceutical products. In addition to its robust and growing internal capabilities, Phlow’s network of established, innovative, and experienced strategic partners will provide high quality, US-based advanced manufacturing solutions for small molecule active pharmaceutical ingredients (APIs) and registered starting materials (RSMs) across all stages of development using state-of-the-art technologies and unique industry insights. (Phlow Corp., News, March 2022)

    Pharmaceutical Continuous Manufacturing Market Report Coverage and Deliverables

    The “Pharmaceutical Continuous Manufacturing Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Pharmaceutical continuous manufacturing market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Pharmaceutical continuous manufacturing market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Pharmaceutical continuous manufacturing market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the pharmaceutical continuous manufacturing market
    • Detailed company profiles